ReviewSeminars in cancer biology2007
Inhibitory costimulation and anti-tumor immunity.
Review in Seminars in cancer biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- A stop-gain variant inHGG advances · 2023Pooled it
- Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- The Role of CD28 and CD8International journal of molecular sciences · 2022Article
- Tet2 and Tet3 in B cells are required to repress CD86 and prevent autoimmunity.Nature immunology · 2020Article
- Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.Cell research · 2017Article
- Oncolytic virus-mediated reversal of impaired tumor antigen presentation.Frontiers in oncology · 2014Review
- A common 56-kilobase deletion in a primate-specific segmental duplication creates a novel butyrophilin-like protein.BMC genetics · 2013Article
- CD28 ligation increases macrophage suppression of T-cell proliferation.Cellular & molecular immunology · 2012Article
- Involvement of Src in the Adaptation of Cancer Cells under Microenvironmental Stresses.Journal of signal transduction · 2012Article
- Targeting costimulatory molecules to improve antitumor immunity.Journal of biomedicine & biotechnology · 2012Review
- T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract.Immunologic research · 2011Article
- Article
- A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States.The Journal of surgical research · 2009Article
- Cutting edge: A critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- The complex role of B7 molecules in tumor immunology.Trends in molecular medicine · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Costimulation was originally shown to be important in T-cell activation and effector differentiation. Recent characterization of B7/butyrophilin and members of the CD28 superfamily has revealed a large number of negative costimulatory molecules that dampen T-cell activation and regulate immune tolerance. Some of these molecules have been shown to be upregulated in the tumor microenvironment and may serve as potential targets for augmenting anti-tumor immunity. In this article, we summarize recent developments in the field of inhibitory costimulation and discuss the future direction of therapeutic manipulation of inhibitory costimulation in tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.